Genelux AAQS

What does Genelux do? Genelux Corp develops and markets oncolytic viral immunotherapies, including Olvi-Vec, a modified vaccinia virus strain for platinum-resistant ovarian cancer, and V2ACT, a personalized anti-cancer therapy enhancing T cell activity. The company focuses on Phase II trials for Olvi-Vec in solid tumors and offers V-VET1, a veterinary oncolytic virus for animal health. Products target patients with solid tumor types and animal health applications, with clinical development driven by the firm's pipeline. The company generates revenue through the development and commercialization of its drug candidates, including Olvi-Vec, V2ACT, and V-VET1, targeting both human oncology and veterinary markets. Clinical trial phases and product development stages define its current focus, with Olvi-Vec in Phase II for ovarian cancer and V-VET1 in veterinary applications. The firm operates with a 15-employee structure, emphasizing pipeline advancement without publicized commercial sales yet. Genelux Corp's product portfolio includes Olvi-Vec for human solid tumors, V2ACT as a personalized immunotherapy, and V-VET1 for animal health. The company's revenue model relies on advancing these therapies through clinical trials, with no current commercial sales disclosed. The firm is positioned to address unmet needs in oncology, particularly in platinum-resistant cancers, and veterinary oncology through its viral-based approaches. Genelux is one of the most popular companies on Eulerpool.